Transgenic blockade of interleukin 6 transsignaling abrogates inflammation.

The immunoregulatory cytokine interleukin6 (IL6) acts in a pro- and anti-inflammatory fashion. Synthesized by myeloid cells, fibroblasts and endothelial cells, IL6 on target cells, binds to the IL6 receptor (IL6R) and signals via complex formation with the ubiquitously expressed gp130 receptor. Paradoxically, most cells that respond to IL6 during inflammatory states do not express the IL6R and are themselves not directly responsive to the cytokine. A naturally occurring soluble form of the IL6R renders all cells responsive to IL6. This alternative signaling process is called IL6 transsignaling. Here we developed a transgenic strategy based on the overexpression of the soluble form of gp130, which specifically blocks all IL6 responses mediated by the soluble IL6R but does not affect IL6 responses via the membrane bound IL6R. In these mice, inflammatory processes are blocked as in IL6(-/-) mice, strongly arguing for a major role of the soluble IL6R during inflammation in vivo.

[1]  C. Fielding,et al.  Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. , 2007, Blood.

[2]  M. Neurath,et al.  Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25− T Cells1 , 2007, The Journal of Immunology.

[3]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[4]  Daniel T. Fisher,et al.  Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism , 2006, Nature Immunology.

[5]  J. Wallace,et al.  Hydrogen sulfide is an endogenous modulator of leukocyte‐mediated inflammation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  J. Scheller,et al.  Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer , 2006, Journal of leukocyte biology.

[7]  M. Sitkovsky,et al.  Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. , 2006, Blood.

[8]  U. Klingmüller,et al.  Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. , 2006, Molecular biology of the cell.

[9]  M. Sata,et al.  STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice , 2006, Gut.

[10]  C. Fielding,et al.  Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. , 2006, Arthritis and rheumatism.

[11]  C. Fielding,et al.  IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Scheller,et al.  No inhibition of IL-27 signaling by soluble gp130. , 2005, Biochemical and biophysical research communications.

[13]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[14]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[15]  S. Govindarajan,et al.  Codon bias and heterologous protein expression. , 2004, Trends in biotechnology.

[16]  T. S. Wilkinson,et al.  Differential Regulation of Neutrophil-Activating Chemokines by IL-6 and Its Soluble Receptor Isoforms1 , 2004, The Journal of Immunology.

[17]  Adil I. Khan,et al.  Leukocyte migration is regulated by L-selectin endoproteolytic release. , 2003, Immunity.

[18]  Stefan Rose-John,et al.  Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)* , 2003, Journal of Biological Chemistry.

[19]  S. Rose-John,et al.  Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.

[20]  Stefan Rose-John,et al.  Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation , 2003 .

[21]  E. García-Ramallo,et al.  Resident Cell Chemokine Expression Serves as the Major Mechanism for Leukocyte Recruitment During Local Inflammation , 2002, The Journal of Immunology.

[22]  P. Bongrand,et al.  Chemotactic agents induce IL‐6Rα shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF‐α‐converting enzyme (TACE) type , 2002 .

[23]  J. Cyster,et al.  Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. , 2001, Immunity.

[24]  P. Bongrand,et al.  The IL-6-Soluble IL-6Rα Autocrine Loop of Endothelial Activation as an Intermediate Between Acute and Chronic Inflammation: an Experimental Model Involving Thrombin , 2001, The Journal of Immunology.

[25]  T. S. Wilkinson,et al.  Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.

[26]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[27]  M. Neurath,et al.  Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis , 2000 .

[28]  M. Baiocchi,et al.  Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. , 1999, Cytokine.

[29]  Simon A. Jones,et al.  Brief Definitive Report C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding , 1999 .

[30]  S. Rose-John,et al.  Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. , 1998, Blood.

[31]  Y. Saeki,et al.  IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. , 1998, International immunology.

[32]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[33]  M. Jordana,et al.  IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. , 1998, The Journal of clinical investigation.

[34]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[35]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[36]  E. Furth,et al.  Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice , 1996, Science.

[37]  S. Rose-John,et al.  Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor , 1996, Infection and immunity.

[38]  S. Rose-John,et al.  Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Wolf,et al.  The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6 , 1996, The Journal of experimental medicine.

[40]  F. J. Luque,et al.  Theoretical Methods for the Representation of Solvent , 1996 .

[41]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[42]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[43]  P. Heinrich,et al.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. , 1994, Journal of immunology.

[44]  C. Stewart,et al.  Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor , 1992, Nature.

[45]  T. Hirano,et al.  Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. , 1991, The Biochemical journal.

[46]  R. Palmiter,et al.  Heterologous introns can enhance expression of transgenes in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. de Vente,et al.  Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice. , 1988, The Journal of biological chemistry.

[48]  P. Lansdorp,et al.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[50]  D. A. Willoughby,et al.  The formation of a structure with the features of synovial lining by subcutaneous injection of air: An in vivo tissue culture system , 1981, The Journal of pathology.

[51]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[52]  R. Hanson,et al.  Phosphoenolpyruvate carboxykinase and pyruvate carboxylase in developing rat liver. , 1967, The Biochemical journal.

[53]  T. Hirano,et al.  IL-6 cytokine family and signal transduction: a model of the cytokine system , 2004, Journal of Molecular Medicine.

[54]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.